- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | Gilead agrees to license new HIV drug in low-income countries | ||
| Mi | Lilly plans $4.5B 'foundry' for advanced drug manufacturing | ||
| Mi | How Roche plans to fill a projected $8B sales gap | ||
| Mi | With $115M more, Triveni accelerates immune drug work | ||
| Di | The top biopharma conferences in 2025 | ||
| Di | IGM lays off staff in autoimmune pivot; Metsera ramps up obesity drug supply | ||
| Di | Kailera Therapeutics emerges from stealth with $400M for obesity drugs | ||
| Di | J&J drops 340B rebate plan after government pressure | ||
| Di | 5 FDA decisions to watch in the fourth quarter | ||
| Mo | Roche turns to a startup in search for new breast cancer drugs | ||
| Mo | Aktis raises $175M to fuel radiopharma drug development | ||
| Mo | Prime to narrow gene editing research as it strikes deal with Bristol Myers | ||
| Mo | Key factors shaping the future of clinical services organizations in the APAC market | ||
| Mo | Accelerating precision oncology: The value of an end-to-end partner for therapeutic access | ||
| Fr | J&J builds case for Talvey; FDA panel questions PD-1 drugs for certain cancers | ||
| Fr | FDA, after delay, clears Regeneron and Sanofi drug for COPD | ||
| Fr | Bristol Myers schizophrenia drug, the first of its kind, approved by FDA | ||
| 26.09. | Pfizer to pull sickle cell drug from market, shut down trials | ||
| 26.09. | Arch raises another $3B biotech fund in pursuit of 'coolest' new science | ||
| 26.09. | BioAge prices $198M IPO, validating pivot to obesity drug research | ||
| 25.09. | An Italian biotech gets $52M to advance pediatric gene therapies | ||
| 25.09. | Struggling 2Seventy scraps a key cancer study | ||
| 25.09. | Amgen claims success for two immune drugs, but results underwhelm Wall Street | ||
| 25.09. | Novo CEO pressed by Senate to cut prices of obesity, diabetes drugs | ||
| 24.09. | Bluebird to lay off another 25% of workforce in latest restructuring |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
